A Phase Ib Open-Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Bevacizumab and Immunotherapy When Administered in Patients With Gastrointestinal and Other Tumors
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cobimetinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastrointestinal cancer
- Focus Adverse reactions
- Sponsors Roche
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 18 Jan 2019 Planned primary completion date changed from 15 Dec 2018 to 1 Aug 2019.
- 28 Jul 2018 Status changed from recruiting to active, no longer recruiting.